Annalisa Morgan, MD, looks forward to discussing the upcoming 2025 ACTRIMS Forum, focusing on disease-modifying therapy use for patients with an inflammatory relapsing-remitting phenotype of multiple sclerosis (MS). There will be debates on how best to characterize MS subtypes, with Dr Morgan suggesting that MS should be seen as a spectrum of disease involving both inflammation and neurodegeneration.
New therapies, such as chimeric antigen receptor (CAR) T-cell therapy, are generating interest owing to their potential for more robust B-cell depletion, alongside other emerging treatments such as Bruton tyrosine kinase (BTK) inhibitors and anti-CD40 ligand therapies. Additionally, the meeting will address aging in patients with MS, particularly safety concerns with disease-modifying therapies, and explore options such as therapy discontinuation or extended-interval dosing in older populations.
